Equities

Fate Therapeutics Inc

Fate Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.00
  • Today's Change0.12 / 3.09%
  • Shares traded1.02m
  • 1 Year change+70.21%
  • Beta1.8302
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy3
Outperform3
Hold11
Sell1
Strong Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for Fate Therapeutics Inc have a median target of 5.50, with a high estimate of 12.00 and a low estimate of 3.50. The median estimate represents a 37.50% increase from the last price of 4.00.
High200.0%12.00
Med37.5%5.50
Low-12.5%3.50

Earnings history & estimates in USD

On Aug 13, 2024, Fate Therapeutics Inc reported 2nd quarter 2024 losses of -0.33 per share. This result exceeded the -0.48 consensus loss of the 18 analysts covering the company and exceeded last year's 2nd quarter results by 38.89%.
The next earnings announcement is expected on Nov 06, 2024.
Average growth rate+10.58%
Fate Therapeutics Inc reported annual 2023 losses of -1.64 per share on Feb 26, 2024.
Average growth rate-9.69%
More ▼

Revenue history & estimates in USD

Fate Therapeutics, Inc. had 2nd quarter 2024 revenues of 6.77m. This bettered the 1.41m consensus of the 15 analysts covering the company. This was 88.52% below the prior year's 2nd quarter results.
Average growth rate+90.31%
Fate Therapeutics, Inc. had revenues for the full year 2023 of 65.53m. This was 31.95% below the prior year's results.
Average growth rate+78.12%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.